ARTH - Arch Therapeutics Inc

From OTC Wiki
(Redirected from ARTH)
Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's products authorized for commercial marketing are AC5 Advanced Wound System and AC5 Topical Hemostat. Arch's development stage product candidates include AC5-GTM and AC5 Surgical Hemostat, among others.

OTC Market: OTCQB

Arch Therapeutics, Inc. is a biotechnology company developing a novel approach to stop bleeding (hemostasis), control leaking (sealant) and manage wounds during surgery, trauma and interventional care. Arch is developing products based on an innovative self-assembling barrier technology platform with the goal of making care faster and safer for patients. Arch's products authorized for commercial marketing are AC5 Advanced Wound System and AC5 Topical Hemostat. Arch's development stage product candidates include AC5-GTM and AC5 Surgical Hemostat, among others.

Jump to: Wiki | News | Links | FAQs | Opinions

Edit Wiki page
Become Wiki Editor
Learn to edit


ARTH Stock - Arch Therapeutics Inc
ARTH Stock - Arch Therapeutics Inc

Arch Therapeutics, Inc. (OTC: ARTH) was founded in 2009 as Almah, Inc. and was engaged in auto parts distribution online. After a reverse merger in 2013 the company became Arch Therapeutics and began "developing polymers comprising synthetic peptides intended to form gel-like barriers over wounds to stop or control bleeding and seal wounds."[1]


Create News


Fri, 10:51 September 23, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Arch Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Fri, 10:51 September 16, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Arch Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Thu, 10:51 September 1, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Arch Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Mon, 11:51 April 4, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Arch Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |


Mon, 11:51 March 14, 2022 | OTC Markets Group - News, Filings & Corporate Actions
Category: Arch Therapeutics, Inc. | Tier: OTCQB | Source: GLOBE |

More News: Company News | OTC Markets

ARTH Stock

As of 11/21/2022 there were 249,886,370 shares of ARTH stock outstanding.

As of 10/31/2022 short interest was 2,487 shares, which represents 1 day to cover.

Symbol change from AAHC to ARTH on 6/5/2013.

Edit Links page

Create FAQs page


Crescendo | Posted on Mar 8, 2022 at 12:36 am | Bear

Let me know when they actually start selling some product. There are a lot of similar products available. What makes theirs any better than the rest, and how are they going to penetrate this market?